Document is current
Any future updates will be listed below
-
Authors
Keller, Sascha
Kunz, Ulrich
Schmid, Ulrike
Beusmans, Jack
Büchert, Martin
He, Min
Jayadeva, Girish
Le Tourneau, Christophe
Luedtke, Doreen
Niessen, Heiko G.
Oum’hamed, Zohra
Pleiner, Sina
Wang, Xiaoning
Graeser, Ralph https://orcid.org/0000-0002-3600-2484
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02674152 at ClinicalTrials.govnct02689505 at ClinicalTrials.govDocuments that mention this clinical trial
Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor
https://doi.org/10.1186/s12967-024-05612-x
Documents that mention this clinical trial
Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor
https://doi.org/10.1186/s12967-024-05612-x
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 21 March 2024
Accepted: 18 August 2024
First Online: 14 October 2024
Declarations
:
: The studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Conference on Harmonization; all patients provided written informed consent for study participation; and the institutional review board approved the study.
: All the authors have consented for publication.
: S Keller, U Kunz, U Schmid, M He, G Jayadeva, D Luedtke, HG. Niessen, Z Oum’Hamed, S Pleiner and R Graeser are or have all been employees of Boehringer Ingelheim. J Beusmans and X Wang are employees of Metrum Research Group. M Büchert and C Le Tourneau declare no competing interests.
